Condition
Ophthalmic Solutions
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results75% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (1)
P 3 (2)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05936489Phase 1Completed
Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
NCT03198000Phase 3CompletedPrimary
A Study to Evaluate the Efficacy of Investigational OTC Eye Drops
NCT03591874Phase 3Terminated
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
NCT02697318Early Phase 1CompletedPrimary
Evaluation of a New Method for Instilling Eye Drops
Showing all 4 trials